Affordable Access

Publisher Website

Whole-body18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
344
Issue
8932
Identifiers
DOI: 10.1016/s0140-6736(94)90753-6
Disciplines
  • Medicine

Abstract

Abstract Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose ( 18FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with "operable" non-small-cell lung cancer who underwent 18FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET identified unsuspected malignant lesions in 10 (29%) patients. Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body 18FDG PET improves preoperative assessment of lung cancer patients.

There are no comments yet on this publication. Be the first to share your thoughts.